标题
PCSK9 as an Atherothrombotic Risk Factor
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 3, Pages 1966
出版商
MDPI AG
发表日期
2023-01-19
DOI
10.3390/ijms24031966
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
- (2022) Na-Qiong Wu et al. Frontiers in Cardiovascular Medicine
- PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction
- (2022) Meidi Utami Puteri et al. Life-Basel
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction
- (2022) Lorenz Räber et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pleiotropic effects of PCSK9-inhibition on hemostasis: Anti-PCSK9 reduce FVIII levels by enhancing LRP1 expression
- (2022) Francesco Paciullo et al. THROMBOSIS RESEARCH
- Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
- (2022) Marcin Basiak et al. Journal of Clinical Medicine
- PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
- (2022) Arianna Toscano et al. Biomolecules
- The Effects of Statin Therapy on Oxidized LDL and Its Antibodies: A Systematic Review and Meta-Analysis
- (2022) Tannaz Jamialahmadi et al. Oxidative Medicine and Cellular Longevity
- Platelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell
- (2022) Alessandro Morotti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PCSK9 inhibition might increase endothelial inflammation
- (2022) Johannes A. Schmid ATHEROSCLEROSIS
- Platelets, coagulation, and the vascular wall: the quest to better understand and smarten up our therapeutic targeting of this triad in primary and secondary prevention of cardiovascular events
- (2021) Bianca Rocca et al. CARDIOVASCULAR RESEARCH
- Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation?
- (2021) J.P.P. Silvino et al. THROMBOSIS RESEARCH
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways
- (2021) Vittoria Cammisotto et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PCSK9 Biology and Its Role in Atherothrombosis
- (2021) Cristina Barale et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players
- (2021) Patrice Marques et al. BIOMEDICINE & PHARMACOTHERAPY
- PCSK9 Induces Tissue Factor Expression by Activation of TLR4/NFkB Signaling
- (2021) Valentina Scalise et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease
- (2021) Álvaro Petersen-Uribe et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study
- (2021) Jia Peng et al. Thrombosis Journal
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome
- (2020) Gregory G. Schwartz et al. CIRCULATION
- The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
- (2020) Nicholas A. Marston et al. CIRCULATION
- PCSK9 Protein and rs562556 Polymorphism Are Associated With Arterial Plaques in Healthy Middle‐Aged Population: The STANISLAS Cohort
- (2020) João Pedro Ferreira et al. Journal of the American Heart Association
- Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
- (2020) Thorsten M. Leucker et al. Journal of the American Heart Association
- PCSK9 and LRP5 in macrophage lipid internalization and inflammation
- (2020) Lina Badimon et al. CARDIOVASCULAR RESEARCH
- PCSK9 Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36
- (2020) Zhiyong Qi et al. CIRCULATION
- Cysteine sulfenylation by CD36 signaling promotes arterial thrombosis in dyslipidemia
- (2020) Moua Yang et al. Blood Advances
- PCSK9 and atherosclerosis: Looking beyond LDL regulation
- (2020) Rosetta Ragusa et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
- (2019) Francesco Paciullo et al. THROMBOSIS AND HAEMOSTASIS
- Platelet function and activation markers in primary hypercholesterolemia treated with PCSK9 monoclonal antibody: a 12-month follow-up
- (2019) Cristina Barale et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers
- (2019) Renate M. Hoogeveen et al. JACC-Cardiovascular Imaging
- Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake
- (2019) Charalambos Vlachopoulos et al. JACC-Cardiovascular Imaging
- Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
- (2018) Angelos D. Karagiannis et al. Current Atherosclerosis Reports
- Rosuvastatin use improves measures of coagulation in patients with venous thrombosis
- (2018) Joseph S Biedermann et al. EUROPEAN HEART JOURNAL
- Improved endothelial function after short-term therapy with evolocumab
- (2018) Guglielmo Maulucci et al. Journal of Clinical Lipidology
- Contribution of lectin-like oxidized low-density lipoprotein receptor-1 and LOX-1 modulating compounds to vascular diseases
- (2018) Anja Hofmann et al. VASCULAR PHARMACOLOGY
- No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia
- (2018) Suzanne Schol-Gelok et al. BIOMEDICINE & PHARMACOTHERAPY
- Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment
- (2018) Lotte C A Stiekema et al. EUROPEAN HEART JOURNAL
- PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia
- (2017) Sophie J. Bernelot Moens et al. EUROPEAN HEART JOURNAL
- Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
- (2017) Eliano P. Navarese et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- PCSK9 and Atherosclerosis - Lipids and Beyond
- (2017) Michael D. Shapiro et al. Journal of Atherosclerosis and Thrombosis
- Role of PCSK9 in the Development of Mouse Periodontitis Before and After Treatment: A Double-Edged Sword
- (2017) Hua Ling Sun et al. JOURNAL OF INFECTIOUS DISEASES
- PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
- (2016) Jin M. Cheng et al. ATHEROSCLEROSIS
- Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk FactorsCLINICAL PERSPECTIVE
- (2016) Karin Leander et al. CIRCULATION
- Twenty-Four-Hour Ambulatory Pulse Wave Analysis in Hypertension Management: Current Evidence and Perspectives
- (2016) Stefano Omboni et al. CURRENT HYPERTENSION REPORTS
- Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study
- (2016) Wuxiang Xie et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inflammatory processes in cardiovascular disease: a route to targeted therapies
- (2016) Neil Ruparelia et al. Nature Reviews Cardiology
- Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease
- (2015) Sha Li et al. ANNALS OF MEDICINE
- Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade
- (2015) S. Magwenzi et al. BLOOD
- Cross-talk between LOX-1 and PCSK9 in vascular tissues
- (2015) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials
- (2015) A. Sahebkar et al. DIABETES OBESITY & METABOLISM
- Prognostic value of PCSK9 levels in patients with acute coronary syndromes
- (2015) Baris Gencer et al. EUROPEAN HEART JOURNAL
- Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches
- (2015) Kyoung-Ha Park et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Local effects of human PCSK9 on the atherosclerotic lesion
- (2015) Ilaria Giunzioni et al. JOURNAL OF PATHOLOGY
- Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease
- (2014) Yan Zhang et al. Journal of Clinical Lipidology
- Lipopolysaccharide augments the uptake of oxidized LDL by up-regulating lectin-like oxidized LDL receptor-1 in macrophages
- (2014) Ekhtear Hossain et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax–caspase9–caspase3 pathway
- (2011) Chun-Yan Wu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now